@Article{ecn.2011.0284,
AUTHOR = {Cihan Meral, Ferhat Cekmez, Sebahattin Vurucu, Emre Tascılar, Ozgur Pirgon, F. Emre Canpolat, Osman Metin Ipcioglu, Gokhan Aydemir, Secil Aydınoz},
TITLE = {New adipocytokines (vaspin, apelin, visfatin, adiponectin) levels in children treated with valproic acid},
JOURNAL = {European Cytokine Network},
VOLUME = {22},
YEAR = {2011},
NUMBER = {2},
PAGES = {118--122},
URL = {http://www.techscience.com/ECN/v22n2/65826},
ISSN = {1952-4005},
ABSTRACT = {Aim. To investigate the relationship between the newly discovered adipocytokines and increasing
body weight (paralleled by increased insulin resistance), and antiepileptic drug therapy with valproic acid (VPA).
Design and methods. 44 children with idiopathic, generalized epilepsy treated with valproic acid (VPA), and 40
control group children were included in this study. Results. Both the VPA-treated group and the control group
showed no significant difference in terms of age, total cholesterol and LDL-cholesterol. Subjects in the VPA group had
significantly higher BMI-SDS than control subjects (2.3±0.15 vs-0.04±0.8, p<0.001). HOMA-IR, apelin and visfatin
levels were significantly increased (4.95±2.07 vs 1.46 vs 0.6, p<0.001; 2.21±1.14 vs 0.57±0.15, p<0.001; 31±12 vs
18.4±10.4, p<0.001; respectively), and adiponectin levels were significantly lower in the VPA group (2.02±1.03 vs
12.4±6.1, p<0.001). Triglyceride levels were significantly increased (126±70 vs 80±40 mg/dL, p=0.001), and HDLcholesterol
levels were significantly lower in the VPA group. Vaspin levels were higher in the VPA group than the
control group, but the difference was not significant. Conclusion. Based on the findings of this study, apelin, visfatin
and adiponectin levels may be considered as potential regulators of glucose and fat metabolism during valproic acid
therapy.},
DOI = {10.1684/ecn.2011.0284}
}